P-0033 Natriuretic Peptide Receptor a As a Novel Target for Gastric Cancer

Jia Zhang,Zhilong Zhao,Ermek Tangsakar,Mingxin Zhang,Jiansheng Wang

DOI: https://doi.org/10.1016/s0923-7534(20)30240-4

IF: 51.769

2012-01-01

Annals of Oncology

Abstract:Introduction The receptor for the cardiac hormone atrial natriuretic peptide (ANP), natriuretic peptide receptor A (NPRA), have been reported to express on lung cancer, prostate cancer, ovarian cancer, NPRA expression and signaling is important for tumor growth, its deficiency protect C57BL/6 mice from lung, skin, and ovarian cancers, and these result suggest that NPRA is a new target for cancer therapy. Recently, NPRA has been demonstrated express in pre-implantation embryos and in ES cells, it has a novel role in the maintenance of self-renewal and pluripotency of ES cells. However, the direct role of NPRA signaling in gastric cancer remains unclear. Methods NPRA expression was examined by western blotting, immunofluorescence and immunohistochemistry. NPRA was downregulated by transfection of siRNA and shRNA. Results we demonstrated that NPRA is abundantly expressed on human gastric cancer AGS cells, but not in nontumorigenic epithelial cells. NPRA expression showed positive correlation with clinical staging and prognosis in gastric cancer patient. Down-regulation of NPRA by siNPRA induced apoptosis in AGS cells. The mechanism of siNPRA-induced anti-AGS effects was linked to NPRA-induced expression of KCNQ1, a K+ channel overexpressed in AGS and significantly reduced by siNPRA. Conclusion Collectively, these results suggest that NPRA promotes gastric cancer development in part by regulating KCNQ1. Our findings also suggest that NPRA is a potential prognostic marker and a target for gastric cancer therapy.